Sage Stock Sinks After FDA Decision on Depression Drug
A split Food and Drug Administration decision on a new depression medicine from Sage Therapeutics and Biogen blew holes in the strategies of both companies and raised questions about the future of their collaboration. Late on Friday, the FDA approved a two-week course of the pill Zurzuvae as a treatment for postpartum depression, but not … Read more